US Viral Vector and Plasmid DNA Manufacturing Market 2026 – 2035

The U.S. market of viral vectors and plasmid DNA manufacturing is estimated to have a market size of USD 3.1 billion in 2026 and increase to USD 10.88 billion in 2035 with an annual growth rate of 20.1% from 2026 to 2035. The market growth can be influenced by the heightened growth of gene and cell therapy pipelines, the escalating clinical trials of advanced therapies, and the growing need for scalable and GMO compliance viral vectors and plasmid DNA by biopharmaceutical firms.

The market growth is also further enhanced by the high concentration of biotechnology companies, increased investments in biologics manufacturing facilities, and a solid regulatory environment to support advanced therapy medicinal products. Besides this, the rising rate of genetic disorders, cancer, and prevalence of rare diseases, the growing trend of outsourcing to contract development and manufacturing organizations (CDMOs); and the development of improved technologies in vector production are all increasing the need for high-quality viral vectors and plasmid DNA manufacturing solutions in the United States.

Market Highlight

• By vector type, adeno-associated virus (AAV) will account for more than 43.1% of total market revenue by 2025, driven by its widespread use in gene therapy and strong safety profile in clinical applications.

• By application, the gene therapy segment will be recording a CAGR of 18.6% in the 2026-2035-time frame with increasing FDA-approved therapies and advanced clinical trials.

• By workflow stage, the upstream processing was almost 39.5% of the total demand in 2025 as more demands are required to scale cell expansion, transfection, and vector production.

• By scale-related manufacturing, commercial scale manufacturing brought in an estimated 45.4% of the market revenue by 2025 with more therapies moving out of clinical development into commercialization.

• By end user, the contract development and manufacturing organizations (CDMOs) had an acquisition of about 32.5% of the market share in the year 2025 as a result of the widespread outsourcing of the biotech and pharmaceutical firms.

Significant Growth Factors

• US viral vectors and plasmid DNA manufacturing market: The U.S. viral vectors and plasmid DNA manufacturing market is growing highly as shown by the rapid growth of gene and cell therapy pipelines in the treatment of oncology, rare diseases, and genetic disorders markets. The industry data also showed that over 50 percent of all clinical trials in the world involving gene therapy in 2024 were based in the U.S., which further stimulated the increase in the GMP-grade viral vectors and plasmid DNA demand. The long-term support of the FDA in the use of advanced therapy medicinal products, including accelerated approval and RMAT designation, has strengthened manufacturing demand. In 2024, the FDA approved a number of gene therapies on the basis of the application of AAV and lentiviral vectors to boost business demands. In addition, gene therapy research is placing a long-term demand on scalable and compliant manufacturing plants in the country due to the rising NIH and private investor funding of the research.

• Capacity Improvements, Capacity Expansion: Capacity expansion is taken to be one of the most important growth aspects as biopharmaceutical companies experience the frustrations of their own production capacity. In 2024, some U.S.-based CDMOs announced an expansion of their facilities to address shortages of vectors and long lead times, in particular of AAV and plasmid DNA. Catalent also grew its cell and gene therapy production footprint in the US through strategic investment, and Thermo Fisher Scientific grew its viral vector productivity in Massachusetts. It has been estimated that over 60 percent of the biotech firms in the United States outsource the production of viral vectors to the CDMOs as a way of cutting production costs and accelerating their timelines. The yields are also increasing as technologies of more suspension cell culture and enhanced transfection systems and scalable downstream purification technologies are being developed, and the risk of batch failures has been minimized to offer scalability in the long run manufacture.

• Gradually Moving Approved Therapies into Commercial Production and Strategic Alliances: This shift in gene therapies out of their clinical stages to commercial production is creating an explosion in large-scale viral vectors and plasmid DNA production in the U.S. There were more than 20 gene and cell therapies on sale in the country and they needed large volumes to be produced consistently. Pharmaceutical companies are engaging in long term contracts to produce goods as a way of protecting capacity risks and supply chains. In 2023–2024 some strategic alliances and acquisitions were observed including alliances of the biotech companies with specialized CDMOs to deliver end-to-end manufacturing services. In addition, growing interest in personalized medicine, along with next-generation gene editing technologies such as the CRISPR-based therapies, is merely ensuring the maintenance of the market by the need for high-quality plasmid DNA.

What are the key Trends transforming the Viral Vector and Plasmid DNA Manufacturing Industry in U.S?

• Ways of Regulatory Evolution and Acceleration of Advanced Therapies: The regulatory environment in the U.S. is currently in the process of changing the manufacturing of viral vectors and plasmid DNA by establishing expedited regulatory routes and providing more optimal steerage of advanced therapies. In 2024, the FDA applied the RMAT and Breakthrough Therapy designations more broadly, which reduced the time to develop them and raised the requirement to manufacture them in compliance and with higher quality. According to the agency, more than 30 percent of new investigational new drug (IND) filings were either gene or cell therapies and this has imposed a burden on manufacturers to have more stringent GMP and quality standards. The manufacturers are also investing in real-time quality monitoring and digital batch records to adjust to the changes. With the reaction to changing regulations to counteract, in 2024 part of CDMOs fully transformed their plants to the FDA and EMA standards and were further prepared to manufacture on the international scale.

• Technology Innovation, Automation and Process Optimization: The U.S. viral vectors and plasmid DNA production are greatly changing the technological technology in order to enhance the yields, consistency, and scale. Importantly, next generation transfection technologies in suspension based cell culture systems have minimized production schedules and contamination possibilities. In 2024, a number of manufacturers in the United States also published automated bioreactor technology, which was capable of generating larger viral titers with less variation. Thermo Fisher scientific introduced other improved single-use bioprocessing platforms to increase the viral vectors' throughput, and Sartorius increased its presence in the United States through automated downstream purification platforms. According to industry estimates, adoption of automation has minimized the batch failure rates by more than 20 percent in large plants and even higher by making the advanced technologies in manufacturing an important competitive differentiator.

• Industry Consolidation, Capacity expansion and Supply chain localization: The U.S. market is also in a remodeling process in consolidation, acquisitions, and expansion in capacity as companies struggle to attain manufacturing capacity. In 2023-2024 a successful wave of acquisitions of large life science firms of specialty Viral vector manufacturers took place to further entrench in-house capacity. The industry estimates had shown that the manufacturing capacity of viral vectors was almost 40 percent of the global manufacturing capacity in the U.S. in 2024. It is also through localization of plasmid DNA production and other important reagents that companies are engaging in the effort of minimizing the use of foreign raw materials. The CDMOs announced long term programs of capacity expansion in Massachusetts, California and North Carolina, supply chain resilience, and reduction of lead times in clients of biotechnology.

Category Wise Insights

By Vector Type

Why is Adeno-Associated Virus (AAV) such a leader in the U.S. market of viral vectors manufacture?

AAV is a leading viral vector manufacturing firm in the United States, holding a dominant market share because of its excellent record of safety, low immunogenicity, and sustained gene expression. It is common in approved FDA gene therapies for rare genetic diseases, neurological diseases, and ophthalmics. Demand is greatly increased by the rising cases of late-stage clinical trials and the commercial launch of gene therapies utilizing AAV. Moreover, there are ongoing developments in AAV capsid engineering and scalable production systems, which have enhanced its dominance in clinical and commercial manufacturing.

What is the reason why Lentivirus is one of the most rapidly expanding segments of vectors?

CAR-T and stem cell-based treatments are some of the most widely used Lentiviral vectors, which are experiencing a swift increase in use. They are appropriate in long-term therapeutic effects because of their capacity to be integrated into the host genome. The increasing number of approvals of cell therapies in the U.S., growing investment in oncology and immunotherapy research are pushing demand for lentiviral manufacturing, particularly at clinical and commercial levels.

By Application

Why is Gene Therapy the market leader in the U.S. viral vectors and the plasmids manufacturing market?

The market is headed by gene therapy since the U.S. is the center of worldwide study, clinical experiment, and implementation of gene therapy. Increased number of therapeutics to treat rare diseases, inherited disorders, and cancers has greatly enhanced the need for high-quality viral vectors and plasmid DNA. There is also enhanced regulation, more funding by both the government and the private sector, and patient awareness, which has increased the manufacturing need in the entire gene therapy segment.

Why is Cell Therapy becoming a high growth application?

The growth of cell therapy is very rapid because of the successful CAR-T therapies and the development of personalized medicine. Viral vectors are required in cell modification and genetic engineering, which has led to consistent demand. Rising approvals, extended indications, and rising investments by the biopharmaceutical firms are making cell therapy a key driver of development in the U.S. market.

By Workflow Stage

What is the reason why Upstream Processing explains a significant portion of manufacturing processes?

Upstream processing is superior because it is essential in the expansion of cells, transfection, and the generation of viral vectors. This is an intensive phase that needs highly developed bioreactor systems, cell line optimization, and high quality raw materials. This has been enhanced by continuous innovation of upstream technologies to enhance yield and scalability and further enhanced its significance in manufacturing workflow.

What is the reason why Downstream Processing is becoming more and more popular?

Strict regulations on purity, safety, and uniformity of products are creating interest in downstream processing. Strategic significance of the stage has been heightened by the need to eliminate impurities, as well as the need to make sure that GMP is being adhered to by investing heavily in new purification and filtration systems.

By Manufacturing Scale

Why is Commercial-Scale manufacturing the top seller?

Large-scale production is predominant with the increasing number of gene and cell therapies shifting to market licensure. Commercial treatments need a large and continuous output, therefore leading to long-term deals between therapy developers and producers. This trend has created a high level of demand of huge scale and GMP compliant manufacturing facilities throughout the U.S.

Why is Clinical-Scale manufacturing still a crunch?

Clinical-scale productions are necessary because the early-stage clinical trials continue to be introduced constantly. Many of the investigational therapies are needed in small batches that are flexible, thus clinical-scale facilities are crucial to innovations and pipeline development.

By End User

Why are CDMOs dominant in the U.S. market?

The contract development and manufacturing organizations (CDMOs) are the predominant ones because biopharmaceutical companies readily outsource to them to achieve cost-efficiency, short timelines, and regulatory experience. The lack of in-house manufacturing capacity and growth in the complexity of viral vectors manufacturing has augmented the dependency on specialty CDMOs throughout the U.S.

What is Driving Biopharmaceutical Companies to invest more in manufacturing?

In order to achieve supply chain security as well as minimize the risk of dependency, biopharmaceutical firms are moving towards internalized manufacturing. The increased significance of viral vectors and plasmid DNA applications to long-term product commercializations is demonstrated by strategic expansions and upgrades of facilities.

Report Scope

Top Players in the Market and Their Offerings

• Thermo Fisher Scientific

• Catalent Inc.

• Lonza Group

• Charles River Laboratories

• FUJIFILM Diosynth Biotechnologies

• WuXi Advanced Therapies

• AGC Biologics

• Oxford Biomedica

• Virovek Incorporation

• RegenxBio Inc.

• Waisman Biomanufacturing

• Genezen

• Others

Key Developments

The U.S. viral and plasmid DNA manufacturing market has experienced a high level of developments, where key players are involved in capacity, technology, strategic alliance and portfolio development to fulfill this increasing demand of gene therapy, cell therapy and vaccine development.

• Thermo Fisher Scientific increased production capacity in viral vectors and plasmid DNA in March 2025 that enhances efficient production to serve both clinical and commercial programs.

• Catalent, Inc. has introduced the service of integrated plasmid DNA and viral vectors in July 2024, which is capable of the development of processes and scale-up of various programs aimed at gene therapy within a shorter time.

• In June 2024 Lonza Group opened new facilities in the U.S. which increased AAV and lentiviral vector production and enabled biopharmaceutical clients to do commercial-scale production.

These business initiatives have assisted firms in diversifying service offerings, strengthening manufacturing strength, optimizing manufacturing, and leveraging growth in the developing U.S. viral vectors and plasmid DNA segment.

The US Viral Vector and Plasmid DNA Manufacturing Market is segmented as follows:

By Vector Type

• Adeno-Associated Virus (AAV)

• Lentivirus

• Retrovirus

• Adenovirus

• Others

By Application

• Gene Therapy

• Cell Therapy

• Vaccines

• Research & Development

By Workflow Stage

• Upstream Processing

• Downstream Processing

• Fill & Finish

By Manufacturing Scale

• Clinical Scale

• Commercial Scale

By End User

• Biopharmaceutical Companies

• Contract Development & Manufacturing Organizations (CDMOs)

• Academic & Research Institutes